Insmed Inc (INSM)vsSol Gel Technologies Ltd (SLGL)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
SLGL
Sol Gel Technologies Ltd
$80.01
+20.86%
HEALTHCARE · Cap: $99.10M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 2434% more annual revenue ($606.42M vs $23.93M). INSM leads profitability with a -2.1% profit margin vs -14.2%. SLGL earns a higher WallStSmart Score of 40/100 (D).
INSM
Hold39
out of 100
Grade: F
SLGL
Hold40
out of 100
Grade: D
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Strong operational efficiency at 65.1%
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
2.2% revenue growth
4.9% earnings growth
Smaller company, higher risk/reward
ROE of -10.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : SLGL
The strongest argument for SLGL centers on Operating Margin.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : SLGL
The primary concerns for SLGL are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
SLGL carries more volatility with a beta of 1.38 — expect wider price swings.
SLGL is growing revenue faster at 2.2% — sustainability is the question.
SLGL generates stronger free cash flow (275,000), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
SLGL scores higher overall (40/100 vs 39/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Sol Gel Technologies Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Sol-Gel Technologies Ltd., a specialty clinical-stage pharmaceutical company, is focused on developing and commercializing topical dermatological pharmaceuticals based on its Israel-patented microencapsulation delivery system. The company is headquartered in Ness Ziona, Israel.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?